What is Iovance Biotherapeutics, Inc.'s revenue?

Iovance Biotherapeutics, Inc. (IOVA) reported revenue of $71.43M in Q1 2026.

How has Iovance Biotherapeutics, Inc.'s revenue changed year-over-year?

Iovance Biotherapeutics, Inc.'s revenue increased by 44.8% year-over-year, from $49.32M to $71.43M.

What is the long-term trend for Iovance Biotherapeutics, Inc.'s revenue?

Over 2 years (2023 to 2025), Iovance Biotherapeutics, Inc.'s revenue has grown at a 1388.7% compound annual growth rate (CAGR), from $1.19M to $263.5M.

Iovance Biotherapeutics, Inc. IOVA Revenue

Revenue at other companies

HTF

Heartflow, Inc. Common StockHTFL

$52.59M+41.3%

Cal-Maine FoodsCALM

$666.95M-53.0%

DJT

Trump Media & Technology GroupDJT

$871.2K+6.1%

ADMA BiologicsADMA

$114.49M-0.3%

Minerals TechnologiesMTX

$546.9M+11.2%

Lincoln Educational Services CorporationLINC

$143.96M+22.5%

Other financials

Income statement

See full

Revenue$71.4M+44.8%

Gross profit$28.9M+338%

Operating income-$81.0M+33.1%

Net income-$79.0M+32.0%

EPS (diluted)-$0.19+47.2%

Balance sheet

See full

Cash & equivalents$196.5M+14.5%

Total debt$46.8M-11.3%

Total equity$721.8M-6.0%

Total assets$925.7M-4.2%

Cash flow

See full

Operating cash flow-$72.1M+30.5%

CapEx$6.6M+6.4%

Free cash flow-$78.7M+28.4%

Valuation

See full

Market cap$1.9B+32.4%

Profitability

See full

Gross margin36.7%+4.1pp

Operating margin-127.2%-31.0pp

Net margin-123.9%-28.4pp

FCF margin-106.8%-27.5pp

Returns & leverage

See full

Return on equity-47.5%-3.7pp

Debt / equity0.1×0.0×

Current ratio3.6×-0.6×

Where this comes from

Reported directly by Iovance Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Iovance Biotherapeutics, Inc.'s revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Iovance Biotherapeutics, Inc.'s revenue?: Iovance Biotherapeutics, Inc. (IOVA) reported revenue of $71.43M in Q1 2026.
How has Iovance Biotherapeutics, Inc.'s revenue changed year-over-year?: Iovance Biotherapeutics, Inc.'s revenue increased by 44.8% year-over-year, from $49.32M to $71.43M.
What is the long-term trend for Iovance Biotherapeutics, Inc.'s revenue?: Over 2 years (2023 to 2025), Iovance Biotherapeutics, Inc.'s revenue has grown at a 1388.7% compound annual growth rate (CAGR), from $1.19M to $263.5M.